Today I am going to talk about two topics. First, I am going to discuss the results from the LEADER trial looking at liraglutide in terms of cardiovascular (CV) risk reduction in patients with type 2 diabetes. Then I am going to talk about the somewhat confusing world of sodium/glucose cotransporter 2 (SGLT2) inhibitors and their effect on renal function.
LEADER[1] was a big CV outcomes trial that looked at liraglutide at its nearly highest dose—the average dose was close to 1.8 mg/day—compared with placebo in about 9300 patients followed worldwide for 3.8 years. They were looking to see whether liraglutide was safe in terms of CV events.
Liraglutide did better than just being safe; it improved outcomes. There was a statistically significant reduction of about 12% in the major adverse cardiovascular events (MACE) outcome, which consisted of CV death, nonfatal myocardial infarction, and nonfatal stroke. There was a 22% very significant risk reduction in CV mortality.
This is the second big—and very significant—CV outcomes trial showing that a type 2 diabetes drug also reduces the risk for CV death.
Comparing LEADER With EMPA-REG
Results in the LEADER trial with liraglutide were different from those in the EMPA-REG[2]trial with
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus Clinical Practice Guidelines (SID/AMD, 2022)
Pediatric Type 2 Diabetes Mellitus
COMMENTARY
Diabetes Drugs: The Latest Good -- and Bad -- News
LEADER and EMPA-REG Trial Updates, and an FDA Warning About Renal Risks
Anne L. Peters, MD
DisclosuresAugust 16, 2016
Today I am going to talk about two topics. First, I am going to discuss the results from the LEADER trial looking at liraglutide in terms of cardiovascular (CV) risk reduction in patients with type 2 diabetes. Then I am going to talk about the somewhat confusing world of sodium/glucose cotransporter 2 (SGLT2) inhibitors and their effect on renal function.
LEADER[1] was a big CV outcomes trial that looked at liraglutide at its nearly highest dose—the average dose was close to 1.8 mg/day—compared with placebo in about 9300 patients followed worldwide for 3.8 years. They were looking to see whether liraglutide was safe in terms of CV events.
Liraglutide did better than just being safe; it improved outcomes. There was a statistically significant reduction of about 12% in the major adverse cardiovascular events (MACE) outcome, which consisted of CV death, nonfatal myocardial infarction, and nonfatal stroke. There was a 22% very significant risk reduction in CV mortality.
This is the second big—and very significant—CV outcomes trial showing that a type 2 diabetes drug also reduces the risk for CV death.
Comparing LEADER With EMPA-REG
Results in the LEADER trial with liraglutide were different from those in the EMPA-REG[2]trial with
Medscape Diabetes © 2016 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Diabetes Drugs: The Latest Good -- and Bad -- News - Medscape - Aug 16, 2016.
Tables
References
Authors and Disclosures
Authors and Disclosures
Author
Anne L. Peters, MD
Professor of Clinical Medicine; Director, Clinical Diabetes Programs, Keck School of Medicine, University of Southern California, Los Angeles, California
Disclosure: Anne L. Peters, MD, has disclosed the following financial relationships:
Served as director, officer, partner, employee, advisor, consultant, or trustee for: (current consultant): Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Novo Nordisk
Served as a speaker or member of a speaker's bureau for: (current speakers bureau member): Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.
Served as a consultant or ad hoc speaker/consultant for: AstraZeneca Pharmaceuticals LP; Abbott Laboratories; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Dexcom; Medtronic MiniMed, Inc.; Merck & Co., Inc.; Roche; sanofi-aventis